🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

50 results for “Istituto Gentili S.r.l.” Clear

  1. LOSARTAN

    Istituto Gentili S.r.l.

    Osteogenesis Imperfecta

    phase 2 small molecule active

    1 trial

  2. METFORMIN

    Istituto Gentili S.r.l.

    bone sarcoma

    phase 2 small molecule active

    1 trial

  3. Neulasta 6 mg solution for injection

    Istituto Gentili S.r.l.

    Severe chronic neutropenia (SCN)

    phase 2 small molecule active

    1 trial

  4. Olaparib, ETOPOSIDE TEVA 20 mg/ml, concentrato per soluzione per infusione, Cisplatino Sandoz 1 mg/ml – Concentrato per soluzione per infusione, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, CARBOPLATINO TEVA 10 mg/ml

    Istituto Gentili S.r.l.

    Extensive-Stage Small-Cell Lung Cancer (ES SCLC)

    phase 2 small molecule active

    1 trial

  5. Proleukin 18 x 106 UI Polvere per soluzione iniettabile o per infusione, DC-VACCINE_IRSTIRCCS

    Istituto Gentili S.r.l.

    neuroendocrine tumors, soft tissue sarcoma

    phase 2 small molecule active

    1 trial

  6. RITION Glutatione, Albunorm 20% "200 g/l, soluzione per infusione"

    Istituto Gentili S.r.l.

    decompensated cirrhosis

    phase 2 small molecule active

    1 trial

  7. Receptor radionuclide therapy with 177Lu-DOTATOC (177Lu- edotreotide or 177Lu-octreotide) in SSTR positive patients: a multicenter, prospective, phase II trial

    Istituto Gentili S.r.l.

    NET, Neuroendocrine Tumor, Other SSTR-positive tumours, NETs retreated with PRRT, Pheochromocytomas and paragangliomas, Bronchopulmonary and other NETs

    phase 2 other active

    1 trial

  8. Rixathon 100 mg concentrate for solution for infusion, Aplo-TCSE TCRaß+CD19+ depleto, Allogeneic peripheral blood-derived NK cells CD3- CD56+, Qarziba 4.5 mg/mL concentrate for solution for infusion, Melfalan Tillomed 50 mg polvere e solvente per soluzione iniettabile/infusione, TEPADINA 100 mg powder for concentrate for solution for infusion, Fludarabina Accord 25 mg/ml Concentrato per soluzione iniettabile o per infusione, Grafalon 20 mg/ml concentrato per soluzione per infusione

    Istituto Gentili S.r.l.

    Patient affected by high risk Neuroblastoma relapsed or in progression after first line treatment.

    phase 2 small molecule active

    1 trial

  9. SELUMETINIB, CASODEX 50 mg compresse rivestite con film, OLAPARIB

    Istituto Gentili S.r.l.

    Metastatic breast cancer

    phase 2 small molecule active

    1 trial

  10. Silycus®

    Istituto Gentili S.r.l.

    Cushing's disease

    phase 2 small molecule active

    1 trial

  11. Stivarga 40 mg film-coated tablets

    Istituto Gentili S.r.l.

    grade 1, 2 and 3 meningioma

    phase 2 small molecule active

    1 trial

  12. TAMBICICLIB 100 mg/10 mL, Solution for Injection, AZACITIDINE , TAMBICICLIB 100 mg/20 mL, Solution for Injection, VENETOCLAX

    Istituto Gentili S.r.l.

    Acute myeloid leukemia

    phase 2 small molecule active

    1 trial

  13. TEMOZOLOMIDE

    Istituto Gentili S.r.l.

    Patients with well differentiated neuroendocrine neoplasia (NENs) not eligible for active antitumoral treatments due to their clinical conditions.

    phase 2 small molecule active

    1 trial

  14. Temozolomide SUN 5 mg hard capsules, Temozolomide SUN 250 mg hard capsules, Temozolomide SUN 20 mg hard capsules, DC-VACCINE_IRSTIRCCS, Temozolomide SUN 100 mg hard capsules

    Istituto Gentili S.r.l.

    Glioblastoma

    phase 2 small molecule active

    1 trial

  15. Trimeton 10 mg/1 ml soluzione iniettabile, OMNIPAQUE 300 mg I/ml soluzione iniettabile, Gazyvaro 1,000 mg concentrate for solution for infusion., TACHIPIRINA 500 mg compresse, MEDROL 16 mg compresse, CORTRIUM 40 mg/2 ml polvere e solvente per soluzione iniettabile

    Istituto Gentili S.r.l.

    Primary Membranous Nephropathy

    phase 2 small molecule active

    1 trial

  16. Ultravist 370 mg/ml soluzione iniettabile

    Istituto Gentili S.r.l.

    Patients with breast lesions undergoing further examination

    phase 2 small molecule active

    1 trial

  17. Xofigo 1100 kBq/mL solution for injection, DELTACORTENE 5 mg compresse, Decadron “4 mg/1 ml Soluzione iniettabile”, Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, SOLDESAM 0,2% gocce orali, soluzione

    Istituto Gentili S.r.l.

    metastatic castration resistant prostate cancer (mCRPC), symptomatic bone-only metastatic castration resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  18. ZENGAC “500 mg Polvere per soluzione per infusione e per uso orale”, Plenvu, polvere per soluzione orale, SELG ESSE polvere per soluzione orale, Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, Vancomicina Mylan 500 mg polvere per soluzione per infusione

    Istituto Gentili S.r.l.

    unresectable hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  19. Pembrolizumab plus autologous dendritic cell vaccine in patients with advanced mesothelioma who have failed prior therapies

    Istituto Gentili S.r.l.

    Mesothelioma

    phase 1 other active

    1 trial

  20. Regorafenib in combination with temozolomide with or without radiotherapy in patients with newly diagnosed MGMT-Methylated, IDH wild-type glioblastoma. A phase I dose-finding study (REGOMA-2).

    Istituto Gentili S.r.l.

    MGMT-Methylated, IDH wild-type glioblastoma

    phase 1 other active

    1 trial

  21. Virus-specific T-cell Immunity for the Treatment of Some Resistant Viral Infections After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

    Istituto Gentili S.r.l.

    Patients who have received an allogeneic haematopoietic stem cell transplant and who have developed post-transplant viral reactivation (CMV, Adenovirus, EBV) resistant to pharmacological therapies.

    phase 1 other active

    1 trial

  22. Cormeto 250 mg capsule molli

    Istituto Gentili S.r.l.

    patients with adrenal incidentalomas and subclinical/mild Cushing’s syndrome

    approved small molecule active

    1 trial

  23. Humira 40 mg solution for injection in pre-filled pen, ORENCIA 125 mg solution for injection in pre-filled syringe, Enbrel 50 mg solution for injection in pre-filled syringe, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, ORENCIA 250 mg powder for concentrate for solution for infusion, Cosentyx 150 mg solution for injection in pre-filled syringe, Enbrel 25 mg solution for injection in pre-filled syringe, Simponi 45 mg/0.45 mL solution for injection in pre-filled pen., Jylamvo 2 mg/ml oral so

    Istituto Gentili S.r.l.

    Juvenile idiopathic arthritis

    approved small molecule active

    1 trial

  24. INFLIXIMAB, INFLIXIMAB

    Istituto Gentili S.r.l.

    Inflammatory Bowel Disease

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources